Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 135

recruiting
3 987
countries
28
conditions
2 109

2 333 trials match your criteria

Transitional cell carcinoma

Not recruiting

Study on the Safety and Effectiveness of MK-2870, Enfortumab Vedotin, and Pembrolizumab for Patients with Advanced Bladder Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Neoplasm

Not recruiting

Study of RLY-4008 for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:RLY-4008

Gastrointestinal stromal tumour

Not recruiting

Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ripretinib

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

Inflammatory bowel disease

Not recruiting

Study Comparing Infliximab Alone or with Immunosuppressive Drugs for Moderate to Severe Crohn's Disease Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid

Inflammatory bowel disease

Not recruiting

Study on the Safety and Imaging of Risankizumab-800CW for Patients with Inflammatory Bowel Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab

Encephalitis autoimmune

Not recruiting

Study on the Effects of Satralizumab for Patients with Autoimmune Encephalitis (NMDAR or LGI1)

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years

Neuromyelitis optica spectrum disorder

Not recruiting

Study on Imlifidase for Treating Acute Inflammation in Patients with Neuromyelitis Optica Spectrum Disorder

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase

Non-small cell lung cancer

Not recruiting

Study of reduced pembrolizumab dosing compared to standard dose in patients with advanced non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Vulval cancer+1

Not recruiting

Study of Pembrolizumab for Patients with Vulvar Squamous Cell Carcinoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.